Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of huntington's disease

Human Gene Therapy

Volumn 13, Issue 16, 2002, Pages 1981-1990

  Regulier E ^a,b   Pereira De Almeida, L ^d   Sommer, B ^d   Aebischer, P ^a,d   Déglon, Nicole ^a,d  

^a EPFL   (Switzerland)

^b Division of Surgical Research and Gene Therapy Center   (Switzerland)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CHOLINE ACETYLTRANSFERASE; CILIARY NEUROTROPHIC FACTOR; COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; PHOSPHOPROTEIN DARPP 32; QUINOLINIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; TETRACYCLINE; TRANSACTIVATOR PROTEIN; HYBRID PROTEIN; PHOTOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE MODEL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TRANSFER; HUNTINGTON CHOREA; INFECTION; LENTIVIRINAE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REGULATORY MECHANISM; SAMPLING; TIME; ANIMAL; BRAIN; CYTOLOGY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALIA; LENTIVIRUS;

ANIMALS; BRAIN; CHOLINE O-ACETYLTRANSFERASE; CILIARY NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; HUNTINGTON DISEASE; LENTIVIRUS; LUMINESCENT PROTEINS; NEURONS; QUINOLINIC ACID; RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; TETRACYCLINE;

EID: 1842868523     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340260355383     Document Type: Article

References (42)

1. Aebischer, P., and Ridet, J. (2001). Recombinant proteins for neurodegenerative diseases: The delivery issue. Trends Neurosci. 24, 533-540.
2. Baron, U., Gossen, M., and Bujard, H. (1997). Tetracyclinecontrolled transcription in eukaryotes: Novel transactivators with graded transactivation potential. Nucleic Acids Res. 25, 2723-2729.
3. Beal, M.F., Kowall, N.W., Ellison, D.W., Mazurek, M.F., Swartz, K.J., and Martin, J.B. (1986). Replication of the neurochemical characteristics of Huntington' s disease by quinolinic acid. Nature 321, 168-171.
4. Bensadoun, J., Pereira De Almeida, L., Dreano, M., Aebischer, P., and Deglon, N. (2001). Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. Eur. J. Neurosci. 14, 1-11.
5. Blau, H.M., and Rossi, F.M. (1999). Tet B or not tet B: Advances in tetracycline-inducible gene expression. Proc. Natl. Acad. Sci. USA 96, 797-799.
6. Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S., and Schreiber, S.L. (1994). A mammalian protein targeted by Gl-arresting rapamycin-receptor complex. Nature 369, 756-758.
7. Corti, O., Sabate, O., Horellou, P., Colin, P., Dumas, S., Buchet, D., Buccaron, M.H., and Mallet, J. (1999). A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nat. Biotechnol. 17, 349-354.
8. De Almeida, L.P., Zala, D., Aebischer, P., and Deglon, N. (2001). Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis. 8, 433-446.
9. De Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P., and Deglon, N. (2002). Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels and protein length. J. Neurosci. 22, 3473-3483.
10. Deglon, N., Tseng, J.L., Bensadoun, J.C., Zurn, A.D., Arsenhevic, Y., Pereira De Almeida, L., Zufferey, R., Trono, D., and Aebischer, P. (2000). Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11, 179-190.
11. Ellison, D.W., Kowall, N.W., and Martin, J.B. (1987). Subset of neurons characterized by the presence of NADPH-diaphorase in human substantia innominata. J. Comp. Neurol. 260, 233-245.
12. Emerich, D.F., Lindner, M.D., Winn, S.R., Chen, E.Y., Frydel, B.R., and Kordower, J.H. (1996). Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16, 5168-5181.
13. Emerich, D.F., Winn, S.R., Hantraye, P.M., Peschanski, M., Chen, E.Y., Chu, Y., Mcdermott, P., Baetge, E.E., and Kordower, J.H. (1997). Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 386, 395-399.
14. Eriksdotter Jonhagen, M., Nordberg, A., Amberla, K., Backman, L., Ebendal, T., Meyerson, B., Olson, L., Seiger, Shigeta, M., Theodorsson, E., Viitanen, M., Winblad, B., and Wahlund, L.O. (1998). Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9, 246-257.
15. Fedorov, L.M., Tyrsin, O.Y., Sakk, O., Ganscher, A., and Rapp, U.R. (2001). Generation dependent reduction of tTA expression in double transgenic NZL-2/tTA(CMV) mice. Genesis 31, 78-784.
16. Frimpong, K., and Spector, S.A. (2000). Cotransduction of nondividing cells using lentiviral vectors. Gene Ther. 7, 1562-1569.
17. Furth, P.A., St Onge, L., Boger, H., Gruss, P., Gossen, M., Kistner, A., Bujard, H., and Hennighausen, L. (1994). Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA 91, 9302-9306.
18. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547-5551.
19. Gossen, M., and Bujard, H. (1995). Efficacy of tetracycline-controlled gene expression is influenced by cell type: Commentary. Biotechniques 19, 213-216.
20. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.
21. Harding, T.C., Geddes, B.J., Murphy, D., Knight, D., and Uney, J.B. (1998). Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat. Biotechnol. 16, 553-555.
22. HD Collaborative Group, T.H.S.D.C.R. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
23. Kafri, T., Van Praag, H., Gage, F.H., and Verma, I.M. (2000). Lentiviral vectors: regulated gene expression. Mol. Ther. 1, 516-521.
24. Kistner, A., Gossen, M., Zimmermann, F., Jerecic, J., Ullmer, C., Lubbert, H., and Bujard, H. (1996). Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA 93, 10933-10938.
25. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., Mcbride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N., and Aebischer, P. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
26. Kordower, J.H., Palfi, S., Chen, E.Y., Ma, S.Y., Sendera, T., Cochran, E.J., Mufson, E.J., Penn, R., Goetz, C.G., and Comella, C.D. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424.
27. Menalled, L.B., and Chesselet, M.F. (2002). Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23, 32-39.
28. Nakagawa, S., Massie, B., and Hawley, R.G. (2001). Tetracycline-regulatable adenovirus vectors: Pharmacologic properties and clinical potential. Eur. J. Pharm. Sci. 13, 53-60.
29. No, D., Yao, T.P., and Evans, R.M. (1996). Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 93, 3346-3351.
30. Olson, L., Nordberg, A., Vonholst, H., Backman, L., Ebendal, T., Alafuzoff, I., Amberlak Hartvig, P., Herlitz, A., Lilja, A., Lundqvist, H., Langstrom, B., Meyerson, B., Persson, A., Viitanen, M., Winblad, B., and Seiger, A. (1992). Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient. J. Neural Transm. Park. Dis. Dement. 4, 79-95.
31. Poduslo, J.F., and Curran, G.L. (1996). Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res. Mol. Brain Res. 36, 280-286.
32. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
33. Suhr, S.T., Gil, E.B., Senut, M.C., and Gage, F.H. (1998). High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. Proc. Natl. Acad. Sci. USA 95, 7999-8004.
34. Urlinger, S., Baron, U., Thellmann, M., Hasan, M.T., Bujard, H., and Hillen, W. (2000). Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc. Natl. Acad. Sci. USA 97, 7963-7968.
35. Varon, S., Manthorpe, M., and Adler, R. (1979). Cholinergic neuronotrophic factors: I. Survival, neurite outgrowth and choline acetyltransferase activity in monolayer cultures from chick embryo ciliary ganglia. Brain Res. 173, 29-45.
36. Vigna, E., Cavalieri, S., Ailles, L., Geuna, M., Loew, R., Bujard, H., and Naldini, L. (2002). Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol. Ther. 5, 252-261.
37. Vonsattel, J.P., and Difiglia, M. (1998). Huntington disease. J Neuropathol. Exp. Neurol. 57, 369-384.
38. Wang, Y., O'Malley, B.W. Jr., Tsai, S.Y., and O'Malley, B.W. (1994). A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA 91, 8180-8184.
39. Werstuck, G., and Green, M.R. (1998). Controlling gene expression in living cells through small molecule-RNA interactions. Science 282, 296-298.
40. Yamamoto, A., Hen, R., and Dauer, W.T. (2001). The ons and offs of inducible transgenic technology: a review. Neurobiol. Dis. 8, 923-932.
41. Yamamoto, A., Lucas, J.J., and Hen, R. (2000). Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66.
42. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., Macdonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R., Timmusk, T., Sipione, S., and Cattaneo, E. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498.